TBX3 and bladder transitional cell carcinoma: A subcutaneous BLCA model was established using TBX3 knockdown or control MB49 cell lines, and the cells were treated with anti-PD-1 or IgG2a isotype antibody every three days for five cycles (Figure 6A).